Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-14	₩10,320.00	+8.63%	27,599
26-07-14	₩9,500.00	-6.59%	90,456
26-07-13	₩10,170.00	-11.49%	36,598
26-07-10	₩11,490.00	+4.93%	31,055
26-07-09	₩10,950.00	+7.88%	44,670

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 2026-07-15			5-day change	1st Jan Change
10,320.00 ^KRW	+8.63%		+2.89%	+280.11%

06-23	Celemics, Inc. announced that it expects to receive KRW 9.999995577 billion in funding from Cnp Co., Ltd.	CI
05-28	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI

Market Cap	101B 67.87M 59.34M 54.74M 50.32M 95.34M 6.53B 96.97M 653M 256M 3.19B 255M 249M 11B	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	95.56B 64.15M 56.08M 51.74M 47.56M 90.11M 6.17B 91.65M 618M 242M 3.02B 241M 236M 10.4B	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	84.27%	Yield 2024 *	-	Yield 2025	-

06-23	Celemics, Inc. announced that it expects to receive KRW 9.999995577 billion in funding from Cnp Co., Ltd.	CI
05-28	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
04-29	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
04-27	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
03-30	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
03-29	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
03-12	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
02-02	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
02-02	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
22-09-19	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
21-03-22	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
20-08-21	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
20-03-18	Celemics, Inc. has filed an IPO.	CI

1 day	+8.63%
1 week	+2.89%
Current month	-13.78%
1 month	-32.42%
3 months	-40.52%
6 months	+285.07%
Current year	+280.11%

Celemics, Inc. Stock

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation: Celemics, Inc.

Chart: Celemics, Inc.

Latest news : Celemics, Inc.

Press Releases: Celemics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	9,250	11,600
1 month	9,250	15,280
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	22,350
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	2016-12-31
Hyo-Gi Kim CEO	Chief Executive Officer	43	2012-12-31
Sang-Seok Lee PRN	Corporate Officer/Principal	45	2019-12-31

Director	Title	Age	Since
Yong-Hun Lee BRD	Director/Board Member	61	2016-12-31
Seung-Kwon Paek BRD	Director/Board Member	62	2025-03-26
Hyo-Gi Kim BRD	Director/Board Member	43	2012-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	+8.63%	+2.89%	+216.56%	+115.67%	62.53M
LONZA GROUP AG	-0.17%	+1.47%	+3.16%	+7.43%	50.35B
REVOLUTION MEDICINES, INC.	-0.04%	-2.56%	+389.05%	+594.89%	39.32B
IQVIA HOLDINGS INC.	+0.06%	+2.53%	+32.52%	-5.61%	34.69B
BEONE MEDICINES AG	+1.62%	+3.31%	+15.63%	+57.58%	34.08B
CELLTRION, INC.	+1.68%	-1.40%	+4.23%	+27.34%	26.63B
ASCENDIS PHARMA A/S	+0.55%	-3.87%	-	-	16.49B
MEDPACE HOLDINGS, INC.	-0.89%	+0.40%	+70.80%	+115.92%	15.31B
EUROFINS SCIENTIFIC SE	+0.43%	+3.34%	+14.96%	+17.98%	13.8B
ICON PUBLIC LIMITED COMPANY	+0.38%	+2.09%	+16.04%	-31.06%	12.87B
Average	+1.21%	-0.94%	+84.77%	+100.02%	24.36B
Weighted average by Cap.	+0.37%	-0.32%	+82.52%	+122.82%

	2024	2025
Net sales	6.72B 4.51M 3.94M 3.64M 3.34M 6.34M 434M 6.44M 43.43M 17.04M 212M 16.94M 16.57M 731M	5.77B 3.87M 3.38M 3.12M 2.87M 5.44M 373M 5.53M 37.28M 14.63M 182M 14.54M 14.22M 628M
Net income	12.27B 8.23M 7.2M 6.64M 6.1M 11.57M 792M 11.76M 79.28M 31.11M 387M 30.92M 30.24M 1.33B	-4.04B -2.71M -2.37M -2.19M -2.01M -3.81M -261M -3.87M -26.09M -10.24M -127M -10.18M -9.95M -439M
Net Debt	-9.55B -6.41M -5.6M -5.17M -4.75M -9M -617M -9.16M -61.71M -24.21M -301M -24.07M -23.54M -1.04B	-5.54B -3.72M -3.25M -3M -2.76M -5.22M -358M -5.31M -35.81M -14.05M -175M -13.97M -13.66M -603M